TLSI News - Candlesense

TriSalus Life Sciences to Participate in Upcoming September Investor Conferences

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care thera...

Investor conference

4 days ago

TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigatio...

Are there any risks or uncertainties highlighted in the release that could affect the stock's volatility in the short term? What is the current cash position and projected runway, and does it raise concerns about dilution from future financing? Did the company issue any forward-looking statements regarding potential FDA milestones or trial readouts that could move the stock?

Earnings

19 days ago

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care thera...

What impact could this have on analyst coverage and future earnings forecasts for TLSI? Is there any indication of upcoming Phase 2 or Phase 3 trials to further validate the PEDD™ technology in thyroid or other indications? How might this development affect TriSalus' competitive positioning relative to other drug delivery technology companies?

Clinical trials

21 days ago